Health · Pharma & Biotech · 3 hrs ago
FDA approves Asahi Kasei’s herpes treatment
Japan’s Asahi Kasei Therapeutics has received approval from the US Food and Drug Administration for a herpes treatment.
The company acquired the treatment earlier this year.
The deal was worth almost $1 billion.
Herpes is the condition the treatment is intended to treat.
The approval gives the treatment FDA clearance.
No further details about the treatment or what happens next were provided.
The FDA approved a herpes treatment developed by Asahi Kasei Therapeutics.
The company acquired the treatment early in 2026.
The acquisition was part of a deal worth almost $1 billion.
The article reported the approval on October 12, 2026.
- Who
- Asahi Kasei Therapeutics and the FDA.
- What
- The FDA approved a herpes treatment acquired by Asahi Kasei Therapeutics.
- When
- The approval date is not stated.
- Where
- Not stated.
- Why
- Not stated.
This story does not have two clearly opposing sides.
Asahi Kasei Therapeutics acquired the treatment in a deal worth almost $1 billion.
Endpoints News reported that the FDA had approved the treatment.
- Company
- Asahi Kasei Therapeutics
- Treatment
- Herpes treatment
- Regulator
- FDA
- Acquisition timing
- Early 2026
- Deal value
- Almost $1 billion
Sources
Related news
Italian Registry Study Finds Avacopan Appeared Effective for AAV
Merck’s eye drug meets main study goal, but results are mixed
Inclisiran lowered LDL cholesterol more than bempedoic acid in a trial
Bristol Myers lung drug succeeds at lower dose, but higher dose misses target
Mirum reports late-stage trial success for Livmarli in rare liver diseases
Bristol Myers reports two Phase 3 trial successes
Aficamten Improves Exercise Capacity in Nonobstructive Heart Condition Trial
GLP-1 drugs may have a role in addiction care, but questions remain
Retatrutide led to major weight loss in a trial involving adults with type 2 diabetes
Lenacapavir and cabotegravir controlled HIV in a small patient study
EU approves evolocumab for adults at high cardiovascular risk
